Edwards Lifesciences (NYSE:EW) Releases FY 2026 Earnings Guidance

Edwards Lifesciences (NYSE:EW) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 2.950-3.050 for the period, compared to the consensus EPS estimate of 3.010. The company issued revenue guidance of $6.6 billion-$6.9 billion, compared to the consensus revenue estimate of $6.7 billion. Edwards Lifesciences also updated its Q3 2026 guidance to 0.710-0.770 EPS.

Edwards Lifesciences Trading Down 0.9%

Shares of NYSE EW traded down $0.74 during trading on Thursday, reaching $83.63. The company had a trading volume of 6,819,679 shares, compared to its average volume of 4,888,525. The stock has a market cap of $48.15 billion, a P/E ratio of 44.48, a PEG ratio of 2.12 and a beta of 0.86. The company’s fifty day moving average price is $87.65 and its 200-day moving average price is $83.90. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 12 month low of $72.30 and a 12 month high of $96.29.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The firm had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, research analysts expect that Edwards Lifesciences will post 3 earnings per share for the current year.

Analyst Upgrades and Downgrades

EW has been the topic of a number of analyst reports. Robert W. Baird upped their target price on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a report on Friday, April 24th. Wolfe Research upgraded Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price target for the company in a research note on Wednesday, April 1st. Citigroup increased their price objective on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Truist Financial lifted their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research report on Thursday, July 16th. Finally, TD Cowen reiterated a “buy” rating on shares of Edwards Lifesciences in a report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and an average target price of $98.95.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 619 shares of the stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $91.70, for a total transaction of $56,762.30. Following the completion of the sale, the vice president directly owned 40,034 shares of the company’s stock, valued at approximately $3,671,117.80. This trade represents a 1.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president directly owned 15,334 shares of the company’s stock, valued at $1,319,950.72. The trade was a 3.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 45,577 shares of company stock worth $3,855,527. Insiders own 0.31% of the company’s stock.

Institutional Trading of Edwards Lifesciences

Several hedge funds have recently made changes to their positions in the company. Quadrant Capital Group LLC raised its position in shares of Edwards Lifesciences by 0.9% in the fourth quarter. Quadrant Capital Group LLC now owns 15,113 shares of the medical research company’s stock worth $1,288,000 after acquiring an additional 136 shares during the period. BOKF NA grew its position in shares of Edwards Lifesciences by 9.8% during the 3rd quarter. BOKF NA now owns 2,214 shares of the medical research company’s stock valued at $172,000 after acquiring an additional 198 shares during the period. L2 Asset Management LLC grew its position in shares of Edwards Lifesciences by 6.8% during the 4th quarter. L2 Asset Management LLC now owns 3,121 shares of the medical research company’s stock valued at $266,000 after acquiring an additional 198 shares during the period. Smartleaf Asset Management LLC increased its stake in shares of Edwards Lifesciences by 3.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 5,962 shares of the medical research company’s stock valued at $514,000 after purchasing an additional 222 shares in the last quarter. Finally, Larson Financial Group LLC increased its stake in shares of Edwards Lifesciences by 8.3% in the 3rd quarter. Larson Financial Group LLC now owns 2,948 shares of the medical research company’s stock valued at $229,000 after purchasing an additional 227 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.